MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study to evaluate a number of intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Key demo aims have been To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyositis sufferers, when on the https://annelin776alx0.wiki-racconti.com/user